Bolloré : First-half 2026 results

Bolloré reported H1 2026 revenue of €1.644 billion, up 8% organically, but EBITA fell 15% to €104 million and net income dropped 45% to €133 million from €242 million. Its listed-securities portfolio declined from €9.232 billion at June 30 to €7.943 billion as of September 14, primarily reflecting a 33% fall in UMG shares; net cash fell to €1.447 billion from €5.619 billion after €4.215 billion in exceptional dividends. The group will receive roughly €2 billion through upstream exceptional dividends following Compagnie de l’Odet's €2.5 billion interim distribution, while it is discontinuing Bluebus electric-bus production and refocusing Blue Solutions on next-generation batteries.

Analysis

BOL is increasingly a look-through vehicle whose valuation will be dictated by UMG rather than its residual operating businesses. The recent UMG mark-to-market decline removes roughly €1.2bn from the value of BOL's principal listed stake, while the weaker contribution from Canal+ reduces the ability of earnings to offset NAV volatility. This argues for further holding-company discount pressure over the next 1-3 months unless UMG stabilizes; Energy's inventory-related uplift is cyclical and should not receive a durable earnings multiple.

The capital-return chain creates a near-term technical opportunity in the controlled listed entities, particularly CBDG, FMONC and ARTO: their proposed distributions are very large relative to free float and will mechanically reset share prices ex-dividend. The relevant question is not headline yield but whether each trades below conservative post-distribution NAV after allowing for withholding, settlement and limited liquidity. BOL's receipt of upstream cash partly replenishes liquidity after its own payout, but does not create new group value; investors should avoid interpreting the circular dividend flow as a balance-sheet de-risking catalyst.

The more constructive second-order development is the exit from electric-bus production. Stopping a subscale, price-competitive activity should cap recurring Industry cash burn and makes fourth-generation battery R&D a cleaner, albeit longer-duration, option. That benefit remains immaterial versus listed-asset exposure until management provides a development budget, commercialization timetable and external customer commitments. The Vivendi control litigation is less acute after the latest ruling, but a further appeal preserves a governance/mandatory-offer tail risk and limits a full discount-to-NAV closure.

Contrarian view: UMG and VIV weakness may be creating an entry point only if BOL's discount widens materially beyond the value of its listed portfolio plus net cash, because the group retains substantial embedded stakes and optionality from simplification. Without evidence of a UMG earnings inflection or a credible monetization program, however, the discount can remain structural rather than mean-revert.

Key Decisions for Investors

• Maintain an underweight/short bias in BOL over the next 1-3 months versus a hedge long UMG only if BOL's holding-company discount is narrower than 25% on updated listed-portfolio NAV. This isolates likely discount widening from a UMG rebound; cover if the discount exceeds 35% or BOL announces asset sales/buybacks funded by surplus cash.
• Do not chase CBDG, FMONC or ARTO into the October distribution dates. Build a watchlist for post-ex-date purchases only after confirming adjusted NAV, tax treatment and average daily liquidity; target a 15%+ discount to conservative post-payout NAV, with a 3-6 month realization horizon.
• Treat UMG as the key catalyst monitor rather than BOL's reported operating result: reassess BOL exposure after UMG's next earnings/guidance update. A stabilization in streaming revenue growth and margin guidance would remove the principal NAV drag; another guidance reset would likely transmit disproportionately to BOL.
• Avoid assigning value to Blue Solutions' battery program until management discloses annual R&D cash burn and third-party validation. A disclosed spending cap or strategic partner would justify reducing the structural-loss discount; continued losses without commercialization milestones falsify the capital-discipline thesis.
• For VIV, remain cautious despite the favorable intermediate legal outcome. Use any litigation-driven rally to reduce exposure unless the final appellate process is resolved; a reversal that revives a mandatory-offer requirement is the principal asymmetric event risk.